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Background
Immunotherapy with anti-CTLA-4 and anti-PD-1 anti-
bodies has demonstrated overall survival benefits in
patients (pts) with metastatic melanoma (MM) com-
pared to previous standard therapy. Two randomised
clinical trials indicate that combined anti-CTLA-4 and
anti-PD-1 antibody therapy increases the response rate
compared to single agent treatment, but is associated
with increased toxicity [1,2]. Both efficacy and toxicity
of anti-PD-1 therapy appear independent of prior treat-
ment with the anti-CTLA-4 antibody ipilimumab. To
date, only limited evidence exists regarding the efficacy
and toxicity of Ipilimumab in pts that have progressed
on treatment with an anti-PD-1 agent.
Methods
We retrospectively identified pts with MM who received
anti-PD-1 therapy (Nivolumab/Pembrolizumab) and were
subsequently treated with ipilimumab. Ipilimumab was
administered at a dose of 3mg/kg every three weeks for
(up to) four doses and response assessed by CT scan 4-6
weeks after the last dose. Efficacy and toxicity outcomes
were determined from clinical records.
Results
The median age was 53 years with all pts having stage
IVc disease and 4 pts (33%) with an elevated LDH at
commencement of Ipilimumab dosing. The median time
between the last dose of anti-PD-1 therapy and the
commencement of Ipilimumab was 8 months (range 2-
14 months). After a median follow-up of over 6 months,
1 patient (8%) achieved a partial remission as their best
response to anti-PD-1 therapy with an additional
6 (50%) having stable disease. Five patients (42%)
received all four doses of Ipilimumab. Two patients
(17%) achieved an objective response to ipilimumab with
another having prolonged stable disease. Four patients
experienced grade 3/4 immune-related adverse events
(irAE) including colitis (n=3) and pneumonitis (n=1).
Conclusions
Ipilimumab therapy can induce responses in patients
who have failed treatment with an anti-PD-1 antibody.
The response rate and clinical benefit rate appears simi-
lar compared to outcomes in pts who have not received
prior anti-PD-1 antibody therapy. Although cases of
severe and/or unusual irAEs such as pneumonitis have
been observed, an analysis of a larger patient cohort will
be required to test the significance of these observations.
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